We would love to hear your thoughts about our site and services, please take our survey here.
Ruane
Apologies if already posted.
Tiziana Life Science PLC (LON:TILS; NASDAQ:TLSA) is worth around 300% more than the current share price based on just two of its potential pipeline developments, according to HC Wainwright. The broker reiterated its US$25 price target and 'buy' rating for the Nasdaq-listed ADS following the biotech's recent updates on two projects: foralumab and StemPrintER. This target, though excludes any contribution in future from foralumab beyond Crohn's disease or milciclib in cancers beyond HCC (liver); or indeed anything from StemPrintER or TZLS-501 (coronavirus), said the broker. “Positive clinical data with foralumab for indications representing massive markets like AD (Alzheimer’s) and MS (multiple sclerosis) could thus constitute a considerable upside to our assumptions,” added analyst Raghuram Selvaraju. Earlier this week, Tiziana reported that Howard Weiner, the chairman of its scientific advisory board, had received a grant from the NIH to investigate foralumab, its nasally delivered anti-CD3 monoclonal antibody (mAb), as a possible Alzheimer's treatment. The grant followed a demonstration by Weiner that unexpectedly found that the nasally delivered anti-CD3 modulated brain microglia in animal models. Activated microglia have been shown in studies to essentially 'erase' memories in mice, said Selvaraju. Tiziana has a worldwide exclusive licence for nasal administration of anti-CD3 mAbs for the treatment of neurodegenerative diseases including Alzheimer’s, noted the analyst, from Brigham and Women’s Hospital, Harvard Medical School, Boston. A breakthrough in Alzheimer’s is being urgently sought. The developments at Tiziana come as Biogen Inc (NASDAQ:BIIB) is readying to launch aducanumab, which, when it goes live will be the only commercially available product developed specifically to treat the disease. Peak sales are tipped to hit US$10bn, and, with pent up demand worldwide, revenues from the Biogen breakthrough are expected to rise rapidly, analysts said. Phase I trials of foralumab have focused on its use as a treatment for multiple sclerosis and Crohn’s disease, respectively, said Selvaraju but plans are in train for phase II studies in both conditions for nasally and orally administered formulations. Selvaraju expects a proof-of-concept study might start for oral foralumab as a treatment for Crohn’s and intra-nasal foralumab for multiple sclerosis within six to 12 months. Tiziana is also working on an inhaled form to address lung inflammation and dysfunction in patients infected with the SARS-CoV-2 coronavirus, which is responsible for the COVID-19 pandemic. On StemPrintER, Selvaraju added that validation data presented at ASCO in posters provided compelling evidence of its predictive power for breast cancer and its superiority over the current standard Oncotype DX. The shares are trading at 96p in London and US$6.50 in ADS form on Nasdaq.
I don't know if any of you are also in Open Orphan but this is what they are doing at the moment I think.
very disappointed, although my main gripe with them is getting locked out of your account after 5 minutes of inactivity. i find i have to log in around 20 times a day.
Vartry and Takeaimfire thank you
Hi Vartry, thanks for that. Just completed the questionairre on Primarybid.com God they need to know everything about you. I declined to give my trading account number. I assume everything is legit and above board, as I'd never heard of them before today. Thanks in anticipation. Sherlock
Vartry...for future reference where can I find out how to apply for shares offered under the primary bid scheme. Would it be through Primarybid.com ?
KingKitega, it's so refreshing to read an intelligent and logical post like yours instead of some of the posts on here (as well as other bb's) spouting that the share price will be 2 quid by 10 o'clock and 3 quid by close of business a week next Tuesday. Let's have more thoughtful informative posts and less of the guestimates of what the price will be by such a date. Most of us on here want the price to go up but none of us have a crystal ball, and to make a post trying to guess the price usually ends up with the poster looking stupid. We all crave and appreciate accurate information which would help us to work out the value of the company and therefore the expected share price, we do not want to read someones guesswork on the share price at a particular date which is usually wrong anyway. It would also make it easier to read the more constructive posts without all the dross inbetween. Rant over.
Anyone know why the pull back in price today ? Haven't noticed any news .
all of a sudden up 40% !!!!
Apologies if already posted https://youtu.be/wycgu0YnoBM
sorry just noticed still showing yesterday's date so no update yet.
Up 9% @$4.45 extended hours
CNBC.com you can create a watchlist and the prices are live.
Not as far as I know.
I find investing.com is brilliant for sending alerts....and its free.
bbtablet thanks for that, done it now.
Rich Ken, just tried the webcast link to register and it appears the link is broken. Could you check and re-post. Cheers.
https://privateharleystreetclinic.com/products/covid-19-test